Trientine Hydrochloride (Waymade-Trientine)

CADTH recommends that Waymade-Trientine should be reimbursed by public drug plans for the treatment of patients with Wilson disease if certain conditions are met. Waymade-Trientine should only be covered to treat patients who have previously tried and demonstrated intolerance to d-penicillamine (DPA). Waymade-Trientine should only be reimbursed if initiated by clinicians experienced in the management of Wilson disease and if the cost of Waymade-Trientine is reduced.